

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 October 2020 (22.10.2020)



(10) International Publication Number
WO 2020/215021 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
C07K 16/18 (2006.01) *G01N 33/566* (2006.01)

(21) International Application Number:

PCT/US2020/028863

(22) International Filing Date:

17 April 2020 (17.04.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/836,016 18 April 2019 (18.04.2019) US

(71) Applicant: **MOMENTA PHARMACEUTICALS, INC.**
[US/US]; 301 Binney Street, Cambridge, Massachusetts
02142 (US).

(72) Inventor: **PATIL, Siddhesh**; 301 Binney Street, Cam-
bridge, Massachusetts 02142 (US).

(74) Agent: **REYNOLDS, Kimberly A.** et al.; Fish &
Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota
55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,

MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: SIALYLATED GLYCOPROTEINS




FIG. 1

(57) Abstract: Pharmaceutical preparations containing hypersialylated immunoglobulins are described. The preparations are stable to shear stress. The pharmaceutical compositions described herein provide pharmaceutically acceptable hslgG compositions that are stable against shear stress (e.g., a significant number of subvisible particles do not form when the formulation is subjected to shear stress, such as agitation, for example, during shipping and thus can be shipped and handled in liquid form.



WO 2020/215021 A1